

- Bipolar disorder is a chronic disease characterized by periods of mania or hypomania, depression or a combination of both (called mixed state).
- The objective of this study was to assess the cost-effectiveness of asenapine compared to olanzapine in the treatment of patients with bipolar disorder experiencing mixed episodes.
- A pharmacoeconomic model was adapted from a UK model to simulate the management of Italian patients with bipolar I disorder with mixed episodes over a five-year time horizon.
- In this analysis asenapine resulted to be superior to olanzapine, both in terms of lower direct costs and better quality of life, and the results were robust to changes in key parameters.

This summary slide represents the opinions of the authors. This study and the article processing charges were supported by an unrestricted grant from Lundbeck Italy SpA, which was not responsible for the study, data analysis, data interpretation, or manuscript writing. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Author(s) 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).